AC Immune gets milestone payment to initiate Phase 2 trial of PI-2620
Category: #health  | By Mateen Dalal  | Date: 2019-09-19 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

AC Immune gets milestone payment to initiate Phase 2 trial of PI-2620

As cases of neurodegenerative diseases like Alzheimer’s and Parkinson’s are on a rise, biopharmaceutical firms are actively engaging in developing new clinical drugs. Companies are also gaining increased funding from partners to further their cause in this field.

AC Immune SA, a clinical-stage biopharmaceutical company that develops a novel treatment for neurodegenerative diseases, recently gained a milestone payment from partner Life Molecular Imaging to commence the Phase 2 trial of Tau PET (positron-emission tomography) tracer PI-2620.

According to reports, PI-2620 is developed using the firm’s patented Morphomer™ discovery platform in a joint venture with Life Molecular Imaging GmbH, a diagnostic imaging and molecular solutions provider.

The drug plays an important role in quantifying and detecting early Tau deposition in the brain. It also displays potential for non-AD Tauopathies like PSP (progressive supranuclear palsy).

Speaking on the move, Prof. Andrea Pfeifer, CEO, AC Immune, said that the clinical development of PI-2620 is built on its superior imaging and properties characteristics, further bolstering the ability of the company’s Morphomer™ technology and its capability to form lucrative partnerships with established companies like Life Molecular Imaging.

Reportedly, in 2014, Life Molecular Imaging and AC Immune entered into a global license deal for commercialization, development and research of AC Immune's Tau PET tracers supporting the diagnosis of potential Tau-related disorders.

In addition to the recent move, the biopharmaceutical firm was earlier awarded a new grant for its groundbreaking alpha-synuclein (a-syn) PET (positron-emission tomography) tracer program by The Michael J. Fox Foundation for Parkinson’s Research (MJFF).

Moreover, over the past four years, the company has received constant grant support from the foundation to advance the study of a-syn PET tracers which, if successful, could offer the world’s first imaging agent competent enough to precisely monitor and detect the progression of PD (Parkinson’s disease).

Source Credit: https://ir.acimmune.com/news-releases/news-release-details/ac-immune-receives-milestone-payment-connection-initiation-phase?field_nir_news_date_value%5bmin%5d=2019

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

ChatGPT’s creator OpenAI proposes regulation of AI by humans

ChatGPT’s creator OpenAI proposes regulation of AI by humans

By Mateen Dalal

OpenAI, the creator of ChatGPT, has reportedly put forward a proposal for the establishment of an international organization to regulate artificial intelligence (AI). Led by CEO Sam Altman, the company believes that AI systems developed within the ne...

Medtronic pledges USD 350 Mn to expand R&D operations in India

Medtronic pledges USD 350 Mn to expand R&D operations in India

By Mateen Dalal

Medtronic, a leading healthcare technology company, has announced plans to expand its R&D center in Hyderabad, India, with a whopping investment of USD 350 million. The existing facility is already the largest center for the company outside the U...

DuPont to buy Spectrum Plastics, anticipates high ROIC by fifth year

DuPont to buy Spectrum Plastics, anticipates high ROIC by fifth year

By Mateen Dalal

American chemical company DuPont de Nemours Inc. reportedly signed a definitive agreement to buy out Spectrum Plastics Group from AEA Investors, a U.S. based private equity firm. The acquisition will reinforce DuPont’s position in booming non-c...